Nyvepria (Pegfilgrastim)

Pegfilgrastim, the active ingredient in Nyvepria, is a long‑acting granulocyte‑colony stimulating factor presented as a sterile powder for subcutaneous injection use. It reduces the duration of neutropenia and related infection risk in patients receiving myelosuppressive chemotherapy. GNH USA supplies Nyvepria as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Nyvepria is a pegylated filgrastim product that supports the neutrophil recovery pathway in patients undergoing cytotoxic chemotherapy. - Chemotherapy‑induced neutropenia: shortens the duration of low neutrophil counts and helps maintain dose intensity. - Stem‑cell mobilization for autologous transplantation: facilitates collection of adequate CD34‑positive cells. - Peripheral blood progenitor cell collection: improves yield of progenitor cells for transplantation.

Common Side Effects: - Bone pain: mild to moderate discomfort often reported in long bones. - Injection‑site reactions: redness, swelling or itching at the administration site. - Fatigue: general tiredness without a specific cause. - Headache: transient mild headache. - Nausea: occasional feeling of queasiness. - Arthralgia: joint aches, usually low‑grade.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain with signs of internal bleeding. - Acute respiratory distress syndrome (ARDS): severe breathing difficulty. - Anaphylaxis: rapid onset of hives, swelling, airway compromise. - Severe allergic reaction: systemic rash, fever, hypotension. - Capillary leak syndrome: rapid fluid shift causing edema and low blood pressure. - Severe bone pain requiring opioid analgesia.

Before using Nyvepria, consider the following safety measures: - Renal impairment: adjust monitoring as reduced clearance may affect exposure. - Hepatic dysfunction: observe for increased incidence of bone pain. - Prior splenic injury or disease: avoid use due to risk of rupture. - Concomitant chemotherapy: coordinate timing to optimise neutrophil recovery. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Pegfilgrastim may interact with other agents that affect bone‑marrow function or immune response. Major Interactions (Avoid): - Cytotoxic chemotherapy administered within 24 h of pegfilgrastim: may reduce efficacy of both agents. - Myelosuppressive antibiotics (e.g., chloramphenicol): can blunt neutrophil response. - High‑dose steroids: may diminish the proliferative effect on neutrophils.

Moderate Interactions (Monitor Closely): - Immunomodulatory drugs (e.g., lenalidomide): monitor blood counts closely. - Anticoagulants: watch for increased bleeding if severe bone pain limits mobility. - Live vaccines: immune response may be altered; assess timing relative to pegfilgrastia administration.